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VitD	 treatment	 of	 CD4+	 T	 cells	 would,	 through	 binding	 of	 liganded	 VDR,	 lead	 to	
epigenetic	 modifications	 affecting	 genes	 involved	 in	 the	 regulation	 of	 cytokine	
production.	 In	 vivo	 we	 show	 that	 VitD	 repletion	 in	 VitD-deficient	 and	 insufficient	
patients	with	early	stage	CKD	has	immunoregulatory	effects	on	circulating	myeloid	DCs	
by	 reducing	 expression	 of	 HLA-DR	 (a	marker	 of	mature	 DC	 phenotype).	 In	 vitro	we	
identify	a	novel	signaling	pathway	in	CD4+	T	cells,	induced	by	VitD.	The	hallmark	effect	
of	 VitD	 on	 CD4+	 T	 cells	 was	 the	 induction	 of	 an	 immunoregulatory	 phenotype	
characterized	 by	 inhibited	 Th1	 and	 Th17	 cytokines	 and	 induction	 of	 the	 anti-
inflammatory	cytokine	IL-10,	a	process	we	show	to	be	regulated	by	induction	of	IL-6	and	
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sites	 of	 action	 (Tomkins	 and	 Martin,	 1970).	 The	 steroid	 hormones	 are	 critically	
important	as	regulators	of	physiological	processes.	In	general,	steroids	are	divided	into	
two	broad	categories	depending	on	the	site	of	synthesis	of	the	mature	hormone	–	either	
















share	 structural	 and	 functional	 characteristics	 with	 the	 corticosteroids	 and	 sex	




cured	by	exposure	to	summer	sunlight	or	artificially	produced	U.V	 light	 (reviewed	 in	





rickets	 (antirachitic)	 (Steenbock,	 1924).	 The	 actual	 identification	 of	 VitD	 and	 its	
structure	was	not	achieved	until	the	1940’s.	These	discoveries	led	to	the	elimination	of	
rickets	 as	 a	major	medical	 disease	 in	 the	 developed	world.	 However,	 following	 the	
second	 world	 war	 an	 outbreak	 of	 idiopathic	 hypercalcemia,	 attributed	 to	 food	
fortification	with	VitD,	resulted	in	skepticism	over	VitD	supplementation	for	health.	The	
discovery	of	the	VitD	endocrine	system	in	1970	and	subsequent	re-classification	of	VitD	














VitD	 is	 a	 fat-soluble	 steroid	 pro-hormone	 that	 requires	 several	 enzymatic	 steps	 for	
activation	 and	 inactivation.	 It	 is	 essential	 for	 both	 the	 absorption	 and	 regulation	 of	
calcium	and	thus	plays	a	central	role	in	bone	mineralization	and	metabolism.	There	are	
two	 environmental	 sources	 of	 VitD,	 Vitamin	 D2	 (or	 Ergocalciferol)	 is	 a	 dietary	









These	 pro-hormones	 are	 then	 carried	 in	 the	 bloodstream	 and	 undergo	
hydroxylation	 catalyzed	 by	 the	 enzymes	 CYP27A1	 (also	 known	 as	 25	 vitamin	 D	





products	 are	 transported	 through	 the	 circulation	 by	 D-binding	 protein	 (DBP	 –	 also	
known	as	group-specific	component	globulin)	(Omdahl	et	al.,	2002),	1,25	VitD	is	lipid	





gland	 release	 parathyroid	 hormone	 (PTH)	 which	 stimulates	 gene	 transcription	 of	
CYP27B1	(Hewison	et	al.,	2000)	in	the	kidneys,	leading	to	increased	circulating	levels	of	
1,25	 VitD.	 This	 increases	 circulating	 levels	 of	 calcium	 concentration	 through	 several	
mechanisms,	 including	 increased	 renal	 and	 intestinal	 absorption	 of	 calcium	 and	
enhanced	osteoclast	activity	in	the	bone,	which	resorb	skeletal	calcium	and	release	it	
into	circulation.	Serum	levels	of	the	active	metabolite	1,25	VitD	are	so	tightly	regulated	
under	 normal	 circumstances	 that	 the	 levels	 are	 practically	 invariant.	 Both	 PTH	 and	
reduced	serum	calcium	induce	CYP27B1	gene	transcription.	Conversely	1,25	VitD	acts	
in	 a	 negative	 feedback	 loop	 to	 inhibit	 both	 CYP27B1	 transcription	 as	 well	 as	 PTH	
production	 and	 aids	 in	 its	 own	 degradation	 through	 activation	 of	 CYP24A1	 gene	







elevated	 phosphate,	 induces	 FGF23.	 Together	 these	 mechanisms	 protect	 from	
hypercalcemia	and	hyperphosphatemia	which	are	both	drivers	of	ectopic	calcification.		
There	is	also	evidence	to	suggest	that	cells	outside	of	the	kidneys	can	express	
CYP27B1	 protein,	 particularly	 cells	 of	 the	 immune	 system	 (Adams	 et	 al.,	 2014),	
establishing	a	potential	for	paracrine	or	autocrine	function	of	VitD	within	immune	cells	
(Adams	and	Hewison,	2012).	Indeed,	in	vitro	studies	using	different	immune	cells	have	
shown	 that	 CYP27B1	 is	 able	 to	 catalyze	 local	 conversion	 of	 25	 VitD	 to	 1,25	 VitD.	
However,	 the	 physiological	 consequences	 of	 this	 extra	 renal	 1,25	 VitD	 production	





























1,25	 VitD	 are	 converted	 by	 CYP24A1	 to	 24	 hydroxylated	 products	 and	 excreted.	
CYP27B1	 is	 tightly	 regulated:	 a	 drop	 in	 serum	 calcium	 levels	 is	 detected	 by	 the	
parathyroid	gland	and	results	in	secretion	of	parathyroid	hormone	(PTH).	Both	PTH	and	
reduced	 serum	 calcium	 and	 phosphate	 concentration	 directly	 stimulate	 CYP27B1	
transcription,	and	thus	increased	1,25	VitD	production.	1,25	VitD,	in	a	negative	feedback	
loop,	down-regulates	its	own	production	by	inhibiting	CYP27B1	transcription	as	well	as	
PTH	 production.	 1,25	 VitD	 has	 multiple	 systemic	 effects	 which	 ultimately	 result	 in	
restoration	 of	 serum	 calcium	 levels,	 as	 well	 as	 re-calcification	 of	 bones.	 FGF-23	 is	
produced	by	osteocytes	and	decreases	circulating	concentrations	of	1,25	VitD,	through	
induction	 of	 CYP24A1	 and	 suppression	 of	 CYP27B1.	 In	 the	 schematic,	 black	 arrows	














other	 nuclear	 receptors,	 with	 different	 functional	 outcomes	 (Lefebvre	 et	 al.,	 2010).	
Association	 with	 RXR	 is	 necessary	 for	 high	 affinity	 DNA	 binding	 of	 VDR.	 RXR	
heterodimers	 bind	 to	 motifs	 that	 consist	 of	 direct	 repeats	 (DR)	 containing	 the	





It	 has	 also	 been	 suggested	 that	VitD	has	 biological	 functions	 independent	 of	
regulating	 de	 novo	 gene	 transcription,	 through	 membrane	 VitD	 receptors.	 This	
possibility	is	based	on	data	showing	rapid	activation	(within	minutes)	of	non-genomic	





The	VDR	 is	 a	member	 of	 the	 nuclear	 hormone	 receptor	 (NHR)	 superfamily.	Nuclear	
receptors	 are	 intracellular	 transcription	 factors	 that	 regulate	 the	 activity	 of	 gene	
networks	 (Carlberg	 and	 Campbell,	 2013).	 The	 VDR	 belongs	 to	 the	 Thyroid/Retinoid	
(class	 II)	 family,	which	also	 includes	 the	 thyroid	 receptor	 (TR),	 retinoic	acid	 receptor	




specific	 response	 elements	 in	 DNA.	 Nuclear	 hormone	 receptors	 share	 two	 highly	
conserved	domain	structures,	a	C-terminal	ligand-binding	domain	(LBD)	and	a	highly-



















of	 VDR	 and	 the	 histone	 acetyl-transferase	 (HAT)	 SRC-1	 has	 been	 demonstrated	
(Masuyama	et	al.,	1997).	The	structural	domains	of	the	VDR	are	shown	in	Figure	1.4	a.		
Most	 NHR	 family	 members	 also	 contain	 amino	 acid	 sequences	 located	 N-






	 As	mentioned	 in	section	1.3,	 the	VDR-RXR	heterodimer	 typically	 recognises	a	
specific	sequence	(known	as	a	VDRE)	comprised	of	two	hexameric	nucleotide	half	sites	
separated	 by	 three	 base-pairs	 known	 as	 “DR3”	 binding	 sites	 (Kerner	 et	 al.,	 1989;	
Umesono	et	al.,	1991)	(Figure	1.3).	The	VDR	itself	has	little	transcriptional	activity	so	
requires	 recruitment	 of	 a	 group	 of	 co-regulatory	 proteins	 to	 form	 a	 co-regulatory	
complex	 (McKenna	 and	 O'Malley,	 2002).	 Within	 this	 complex	 at	 least	 one	 of	 the	
components	will	contain	a	VDR-interacting	member	and	usually	comprises	numerous	
sub-units.	The	complex	can	include	enzymes	with	ATPase	activity	that	can	modify	the	
nucleosome	 structure,	 enzymes	with	 histone	modifying	 abilities	 (such	 as	 SRC-1	 and	
p300	 (Masuyama	et	al.,	1997),	and	“mediator	complexes”	 that	aid	 in	 recruitment	of	
RNA	 polymerases	 (such	 as	 TFIIB	 (MacDonald	 et	 al.,	 1995).	 The	 recruitment	 of	 the	
complex	seems	to	be	gene	specific,	with	specific	VDREs	in	specific	genes	leading	to	the	
recruitment	 of	 a	 co-regulatory	 complex	 consisting	 of	 different	 proteins	 (Pike	 et	 al.,	














activation	 (Meyer	 et	 al.,	 2010),	 which	 is	 in	 contrast	 to	 other	 steroid	 receptors.	
Interestingly,	these	loci	seem	to	have	a	lower	rate	of	DR3-type	sequences	compared	to	
1,25	VitD	dependent	loci	(Heikkinen	et	al.,	2011)	and	are	associated	with	VDR	repressed	










RXR.	 In	 contrast,	 some	 NHR	 isoforms	 are	 generated	 through	 differential	 promoter	



















suggesting	 the	 existence	 of	 a	 membrane	 bound	 64.5	 kDa	 VDR,	 identified	 in	 chick	
intestinal	epithelium,	able	to	block	1,25	VitD	rapid	signaling	(through	protein	kinase	C)	
in	rat	chondrocytes	(Nemere	et	al.,	1998).	As	of	yet,	there	is	little	evidence	to	suggest	










2-9	 which	 encode	 the	 canonical	 VDR-A	 isotype,	 which	 has	 6	 broad	 domains	 (A-F).	
Functional	domains	are	colour	coded	and	consist	of	the	highly-conserved	DNA	binding	
(green)	 and	 hormone	 ligand-binding	 domain	 (red).	 VDR	 bound	 to	 ligand	 can	 be	
stabalised	by	phosphorylation	of	serine	51	by	protein	kinase	C	and	serine	208	by	casein	
kinase	 II.	 Ligand	 bound	 VDR	 allows	 interaction	 of	 AF-2	 region	 with	 stimulatory	 co-
activators.	Non-synonymous	(FokI)	and	synonymous	(BsmI,	ApaI,	TaqI	and	Tru9I)	single-











Epigenetics	 is	 a	 term	 denoting	 the	 set	 of	 processes	 that	 alter	 gene	 activity	without	
altering	DNA	 sequences.	Maintenance	of	 normal	 functioning	of	 cellular	 processes	 is	
highly	dependent	on	the	interactions	between	different	epigenetic	mechanisms.	These	
include	DNA	methylation	and	histone	modifications,	discussed	in	more	detail	below.		






Thus,	 epigenetic	marks	 on	 genomic	 DNA	 provide	 stable	 and	 long	 lasting	 regulatory	
“decisions”	 about	 gene	 expression,	 as	 is	 observed	 in	 terminally	 differentiated	 cells	
(Mohn	and	Schübeler,	2009),	representing	a	form	of	cellular	“decision”	for	phenotype,	
especially	as	daughter	cells	“inherit”	epigenetic	information	from	parent	cells.	Despite	




genome	 that	 are	 nucleosome	 depleted,	 and	 therefore	 accessible	 using	 a	 technique	
called	FAIRE-seq	 (Formaldehyde-Assisted	 Isolation	of	Regulatory	Elements)	 (Giresi	et	
al.,	2007).	The	only	study	assessing	this	in	relation	to	VitD	is	a	time-course	FAIRE-seq	on	
THP-1	cells	(Seuter	et	al.,	2013)	(a	human	monocyte	cell	line).	In	this	study	87.4%,	of	the	
1034	most	 prominent	 VDR	 ChIP-seq	 peaks	 aligned	with	 regions	 of	 open	 chromatin.	








CpG	 (cytosine	 followed	 by	 guanaine,	 used	 to	 distinguish	 the	 single	 stranded	 linear	
sequence	 from	 CG	 base	 pairing)	 sequences	 (Bird,	 1980).	 Regions	 of	 DNA	with	 high	
frequencies	 of	 CpG	 sites	 are	 known	 as	 CpG	 islands	 and	 hyper-methylation	 at	 these	
















nucleosomes.	 A	 single	 nucleosome	 has	 147	 basepairs	 (bp)	 of	 DNA	 coupled	with	 an	
octomeric	core	of	histone	proteins.	These	consist	of	a	pair	of	H3-H4	histone	dimers	and	
a	pair	of	H2A-H2B	dimers	(Figure	1.5).	In	the	process	of	wrapping,	the	histones	tails	are	
left	exposed	and	 these	N-terminal	 tails	 can	undergo	post-translational	modifications	
which	 allow	 nucleosomes	 to	 shift,	 the	 chromatin	 to	 relax	 and	 genes	 to	 become	
activated	(Campos	and	Reinberg,	2009).	 In	 this	way	histone	modifications	can	act	as	


















state	 awaiting	 external	 cues	 to	 become	 active	 and	 initiate	 gene	 transcription	
(Creyghton	et	al.,	2010).		
	 Active	1,25	VitD	bound	to	VDR	can	both	transactivate	and	transrepress	target	




(Fetahu	et	al.,	2014).	Many	of	 the	members	of	 the	co-regulatory	complex,	 including	
SRC1,	2	and	3	p300	and	CBP,	recruited	by	VDR,	have	lysine	acetyltransferase	activity,	
and	treatment	of	THP-1	cells	with	1,25	VitD	leads	to	increased	H3K27Ac	in	the	promoter	
of	many	VitD	target	genes	 	 (Seuter	et	al.,	2013).	Additionally,	 in	MDA-MB453	breast	
















H3K4	 H3K9	 H3K14	 H3K27	 H2BK5	
mono-methylation	 activation	 activation	 	 activation	 activation	
di-methylation	 	 repression	 	 repression	 	
tri-methylation	 activation	 repression	 	 repression	 	





(TB)	 could	 be	 cured	 using	 light	 irradiation,	 coupled	 with	 the	 discovery	 U.V	 light	
promotes	epidermal	synthesis	of	VitD,	heralded	the	beginning	of	interest	on	the	effects	





expression	 of	 the	 antimicrobial	 peptide	 cathelicidin	 as	 well	 as	 CYP24A1,	 leading	 to	
intracellular	pathogen	killing	(Liu	et	al.,	2006).	This	confirmed	earlier	observations	of	
extra-renal	production	of	1,25	VitD	from	25	VitD,	leading	to	elevated	serum	1,25	VitD	
in	 patients	 with	 granulomatous	 diseases	 (Kallas	 et	 al.,	 2010).	 Combined	 with	 early	








VitD	 through	 inducible	 expression	 of	 the	 CYP27B1	 (Provvedini	 et	 al.,	 1983).	 These	
findings,	along	with	strong	epidemiological	evidence	linking	VitD	deficiency	to	multiple	
autoimmune	diseases,	 suggest	 a	physiological	 role	 for	VitD	 in	 immune	homeostasis.	
Experimentally,	 VitD	 metabolites,	 particularly	 1,25	 VitD,	 have	 multiple	 effects	 on	
immune	system	functioning	that	are	both	antimicrobial	and	immunoregulatory.	Thus,	
VitD	seems	to	play	a	dichotomous	role	 inducing	 intracellular	antimicrobial	actions	of	






VitD	 has	 clear	 effects	 on	 immune	 system	 functioning,	 classically	 characterised	 by	


















































retain	 expression	 of	 the	 VDR	 (Essen	 et	 al.,	 2010).	 However,	 the	 kinetics	 of	 VDR	
upregulation	in	naïve	vs	memory	T	cells	has	not	been	tested.	A	final	complication	is	that	
very	 few	 studies	 of	 direct	 VDR	 expression	 and	 effect	 of	 VitD	 on	 T	 cells	 distinguish	















little	 effect	 of	 VitD	 treatment	 on	 CD4+	 T	 cell	 proliferation,	which	 is	 contrary	 to	 the	
classical	effects	of	inhibition	of	proliferation	(Rigby	et	al.,	1984),	suggesting	that	the	in	
vitro	model	may	not	reflect	in	vivo	effects.	Surprisingly,	the	ability	of	VitD	to	increase	
CTLA-4	 expression	 is	 actually	 increased	 in	 the	 presence	 of	 Th17	 skewing	 conditions	
(Jeffery	 et	 al.,	 2015).	 Additionally,	 a	 VitD	 analogue	 (TX527)	 is	 able	 to	 trigger	 the	
emergence	 of	 CD4+CD25highCD127low	 Treg	 phenotype,	 a	 phenotype	 associated	 with	
“classical	Tregs”	and	strong	immunosuppressive	ability	(Baeke	et	al.,	2011).		
	 VitD	also	has	a	profound	effect	on	the	migratory	signature	of	CD4+	T	cells	by	








known	 to	 be	 vital	 as	 a	 mediator	 of	 the	 innate	 immune	 response,	 enhancing	
antimicrobial	properties	of	innate	immune	cells	(Agrawal	and	Yin,	2014).	
Monocyte	activation	with	IFNγ	or	LPS,	results	in	up-regulation	of	both	CYP27B1	
as	well	 as	 the	VDR	 (Fabri	 et	 al.,	 2011).	Autocrine	engagement	of	 the	VDR	 results	 in	
production	of	natural	anti-microbial	peptides,	such	as	cathelicidin	antimicrobial	peptide	





can	 activate	 other	 innate	 immune	 cells,	 such	 as	 monocytes	 and	 macrophages,	
promoting	proliferation	and	secretion	of	highly	inflammatory	IL-1	(Baeke	et	al.,	2010b).	
Though	a	direct	mechanistic	link	has	been	reported	between	VitD	and	clearance	
of	 tuberculosis	 (see	 section	1.4),	 a	process	 involving	VitD	effects	on	monocytes	 and	
increased	antimicrobial	peptide	cathelicidin	(see	section	1.4)	(Liu	et	al.,	2006),	indirect	
evidence	 of	 benefits	 of	 VitD	 for	 clearance	 of	 other	 types	 of	 infections	 also	 exists.	
Epidemiological	 evidence	 links	 VitD	 deficiency	 with	 increased	 rates	 of	 respiratory	
infections	 (Ginde	et	al.,	2009;	Laaksi	et	al.,	2007)	as	well	as	suggestions	of	epidemic	
winter	influenza	being	a	result	of	VitD	deficiency	.	These	studies	indicate	a	role	for	VitD	
in	 clearance	 of	 a	 range	 of	 infections	 and	 the	 mechanism	 is	 likely	 to	 be	 through	
















clear	 is	 that	 for	 different	 clinical	 and	 biological	 readouts	 this	 value	 may	 vary	
considerably.	A	recent	report	by	the	institute	of	medicine	(IOM)	defined	insufficiency	







inflammatory	 bowel	 disease	 (Dadaei	 et	 al.,	 2015),	 type	 1	 diabetes	 and	 rheumatoid	
arthritis	(Hong	et	al.,	2014).	VitD	also	prevents	acute	graft	rejection	after	liver,	kidney	
and	heart	 transplantation	 (Stein	and	Shane,	2011).	Human	trials	of	VitD	 repletion	 in	
allograft	rejection	are	limited.	In	kidney	transplant	recipients	calcitriol	(another	name	
for	1,25	VitD)	supplementation	was	associated	with	 fewer	episodes	of	acute	cellular	

















Few	 randomised	 placebo-controlled,	 double	 blind	 studies	 have	 examined	 the	























human	 genome	 can	 be	 influenced	 by	 VitD	 (Bouillon	 et	 al.,	 2008),	 including	 steroid	




on	study	cohorts’	 serum	VitD	concentrations	are	 important	and	 relevant	 to	patients	
with	CKD,	on	dialysis	or	after	renal	transplantation	(Elder,	2007).			
Third,	 the	 species	 and	 route	 of	 administration	 of	 VitD	 treatment	 used	 in	
interventional	studies	 is	confounding.	There	are	6-8	different	possible	forms	of	VitD,	




have	 different	 affinities	 for	 the	 VDR,	 potencies,	 biological	 activities,	 and	 side-effect	
profiles	 (for	 a	 detailed	 discussion	 see	 (Kalantar-Zadeh	 and	 Kovesdy,	 2009)).	 Further	
variables	 include	 the	 route	 (oral,	 intramuscular	and	 intravenous	–	 the	 latter	 confers	
greater	 bioavailability)	 and	 frequency	 of	 administration,	 whether	 daily,	 weekly	 or	
monthly.	Additionally,	although	there	is	a	high	prevalence	of	VitD	insufficiency,	there	is	
no	consensus	dosing	strategy	for	VitD	repletion.		











In	 vivo:	 We	 hypothesised	 that	 oral	 repletion	 with	 cholecalciferol	 in	 VitD	
insufficient/deficient	 adult	 patients	 with	 CKD	 stage	 3b/4	 over	 52	 weeks	 would	
ameliorate	systemic	inflammation.	The	work	in	this	thesis	focused	solely	on	the	in	vivo	
effects	of	VitD	on	immune	function		









b) Studying	 the	 mechanisms	 underlying	 VitD	 induced	 IL-10	 production,	











Fifty	 adult	 patients	 (age	18-75)	with	 “early”	CKD	 (clinical	 stages	 3b-4),	mild	CVD	and	
hypovitaminosis	D	(serum	25	(OH)D	levels	between	12.5	to	75	nM)	were	recruited	into	
the	trial	following	institutional	approval.	Patients	were	excluded	from	recruitment	if	they	





or	 trauma,	 fibrotic	 diseases	 or	 active	 inflammatory	 conditions,	 immunosuppressive	
medications,	 presence	 of	 arterio-venous	 fistula	 for	 dialysis	 access,	 and	 history	 of	
previous	myocardial	infarction.	




to	be	safe	and	effective	 in	CKD	patients	 (Chandra	et	al.,	2008).	Serum	25	VitD	 (using	







Week	 -2	 0	 4	 8	 12	 24	 42	 52	
Oral	VitD3	100,000	IU	 	 X	 X	 X	 X	 X	 X	 	
PBMC	collection	 	 X	 	 	 	 	 	 X	
25	VitD	measurement	
(serum)	




























for	 surface	 staining	 and	 fluorescence	 minus	 one	 (FMO)	 controls.	 Cells	 where	 first	
incubated	 with	 Zombie	 Yellow	 viability	 dye	 (Biolegend)	 according	 to	 manufacturer’s	
protocol	followed	by	Fc	blocking	in	human	serum	for	20	min.	Cells	were	then	incubated	
with	surface	conjugated	antibodies	(4°C,	20	min,	100μl	volume	of	FACS	buffer)	 in	the	
dark.	 	 Antibody	 concentrations	 were	 variable	 and	 defined	 determined	 in	 previous	

































































































Patient	 serum	was	collected	 in	plastic	 serum	EDTA	coated	 tubes	 (BD	bioscience)	and	
stored	at	-80°C	in	aliquots	of	500μl.	Serum	samples	were	then	thawed	and	analysed	for	






Biotech)	 according	 to	 manufacturer's	 instructions.	 Monocyte-derived	 DCs	 (mo-DCs)	
were	 generated	 by	 5-day	 culture	 of	 CD14+	 monocytes	 cells	 in	 complete	 RPMI	 1640	















































































































































Memory	CD4+	T	Cell	 isolation	kit	human	 (MiltenyiBiotec)	was	used	 to	 isolate	memory	
CD4+	T	 cells	 for	 ChipSeq	 analysis,	 following	manufacturers	 protocol.	 Following	 culture	




























at	 a	density	of	1	bead	per	4	 cells.	Cells	were	additionally	 cultured	 in	 the	presence	or	
















DNA	 digestion,	 according	 to	 manufacturer’s	 instructions.	 RNA	 concentration	 was	




in	 a	 20µl	 reaction	 volume	 containing	10ng	of	 cDNA.	All	 reactions	were	 carried	out	 in	




provided).	 The	 cycling	 profiling	 was	 as	 follows:	 10	 min	 at	 95oC,	 then	 40	 cycles	 of	
amplification	(each	cycle	consisting	of	15s	at	95oC	then	60s	at	60oC),	followed	by	melt	
curve	analysis	to	ensure	amplification	of	a	single	product.	Comparative	Ct	method	was	






1	 in	 250	 dilution.	 Protein	 concentration	was	 quantified	 using	 quickstart	protein	 assay	
(BioRad).	Proteins	were	resolved	by	SDS-PAGE	on	10%	Tris-Glycine	gels	(Invitrogen)	and	












donors	were	 activated	 in	 the	 presence	of	 ethanol-carrier	 and	VitD,	 lysed	 and	protein	
concentration	 was	 quantified	 using	 quickstartTM	 protein	 assay	 (BioRad).	 Lysates	 were	
normalized	to	a	concentration	of	800µg/mL	using	lysis	buffer.	Membranes	dotted	with	
biotlinylated	anti	phospho-protein	antibodies	were	then	blocked	for	one	hour	at	room	
temperature	 before	 addition	 of	 lysates	 and	 overnight	 incubation	 at	 4°C	 on	 a	 rocker.	
Following	three	washes	in	washing	buffer	detection	antibody	was	added	to	membranes	



















Cells	 were	 activated	 with	 Phorbol	 12-myristate	 13-acetate	 (PMA)	 (50ng/mL,	 SIGMA),	
ionomicyn	(1ug/mL,	SIGMA),	GolgiStop	(1X,	BD)	and	Brefeldin	A	(1X,	BD)	for	5	hours	in	
fresh	culture	media	at	37°C	5%	CO2.	Cells	were	then	washed	in	PBS,	initially	stained	for	
























cells	were	 removed	with	Ficoll-Hypaque	density	gradient	 centrifugation	 (Lymphoprep,	








activated	anti-CD3/CD28	beads	 (ThermoFisher)	 in	a	4:1	ratio	cell:bead	 for	72	hours	at	
37°C,	 5%CO2	 with	 1,25	 dihydroxy	 Vitamin	 D3	 (10nM)	 (Enzo	 life	 sciences)	 or	 carrier	

















1.25	M	glycine	was	 then	added	to	neutralize	 fixation.	Cells	where	 then	centrifuged	at	
1000	x	g	for	5	min	and	supernatant	discarded.	
To	lyse	cells	and	obtain	pure	nuclei	the	following	procedure	was	carried	out:	Two	mL	









removed	 to	 check	 nuclei	 integrity	 and	 number	 using	 2%	 Trypan	 blue	 cell	 counting	 in	
haemocytometer.	Chromatin	was	incubated	with	100unit	(U)/µL	at	37°C	for	10	min	at	
















was	 checked	 with	 this	 fraction	 using	 a	 high	 sensitivity	 DNA	 chip	 (Agilent)	 on	 a	 2100	
Bioanalyzer	(Agilent).		
For	 histone	 modification	 ChIPseq	 (H3K27ac	 and	 H3K4me3)	 no	 cross	 linking	 was	







To	 this,	 5µg	 of	 respective	 antibody	 (H3K27Ac	 ab4729,	 polyclonal,	 Abcam/	 H3k4me3	














Phenol:choloroform:isoamylalcohol	 in	 a	 ratio	 25:24:1	was	 added	 in	 equal	 volumes	 to	
each	sample	and	vortexed	for	30	seconds	and	spun	at	13,000	rpm	for	15	min.	The	upper,	




	 Samples	 were	 then	 thawed	 and	 spun	 at	 13,000	 rpm	 for	 15	 min	 at	 4°C	 and	
supernatant	discarded.	1mL	of	ice	cold	70%	ethanol	was	added	to	wash	pellet	and	sample	
spun	again	at	13,000	rpm	for	15	min	at	4°C	and	supernatant	discarded.	Pellet	was	then	
















































generation	 sequencing	 (NGS)	 analysis	 platform	 Galaxy	 (Afgan	 et	 al.,	 2016).	 FastQC	




























Prior	 to	 further	 analysis	 in	 Easeq	 all	 ChIP-seq	 signal	 from	 bamfiles	 were	 quantile	
normalised	to	ensure	linear	normalisation	for	local	comparisons	of	ChIPseq.		
Data	 from	public	 repositories	was	 accessed	as	 sequence	 read	archives	 (SRA)	 after	
which	they	were	subjected	to	the	same	data	analysis	as	above.	One	important	difference	
was	 bedtools	 “genomecoveragebed”	 tool	 was	 used	 to	 convert	 to	 BedGraph	 and	
“begrpahtobigwig”	 to	 convert	 to	 BigWig	 and	 in	 the	 process	 normalised	 to	 reads	 per	












































common	 cause	 of	 death	 is	 accelerated	 CVD	 with	 the	 second	 most	 common	 being	
infections.	ESKD	patients	have	a	relative	risk	of	CVD	of	up	to	3.4	compared	to	the	general	
population	 (Go	 et	 al.,	 2004).	 This	 can	 only	 partially	 be	 explained	 by	 the	 clustering	 of	
traditional	CV	risk	factors	(hypertension,	hyperlipidaemia	and	obesity)	in	these	patients	




as	 chronic	 inflammation,	oxidative	 stress	 (Cachofeiro	et	al.,	 2008)	and	VitD	deficiency	
(Inaguma	et	al.,	2008)	also	discussed	in	section	1.5.1.		
Patients	with	CKD	are	known	to	be	deficient	in	both	25	and	1,25	VitD	with	several	
observational	 studies	 showing	 that	 treatment	 of	 patients	 with	 VitD	 analogues	 is	
associated	 with	 improved	 survival	 (Kalantar-Zadeh	 et	 al.,	 2006;	 Kimmel	 et	 al.,	 1998;	






postulated	 involvement	 in	 multiple	 diseases	 involving	 the	 immune	 system,	

















and	 that	 VitD	 has	 pleiotropic	 immune	 functions,	 immune	 phenotyping	 of	 peripheral	























number	 of	 cells	 being	 used	 for	 ex	 vivo	 phenotyping,	 we	 sought	 to	 determine	 which	
controls	were	essential	for	accurate	gating.	Current	guidelines	suggest	that	the	best	way	
to	determine	the	difference	between	no	expression	and	low	expression	of	a	particular	




without	 FMO	 controls	 (Figure	 3.2	 a	 and	 b).	 Similarly,	 Tregs	 were	 easily	 identified	 as	
CD4+CD25hiCD127lo	 T	 cells	 (Figure	 3.2	 c).	 Reliably	 discriminating	 between	 FoxP3+	 and	
FoxP3–	human	cells	is	difficult	with	an	isotype	control.	Thus,	CD4+CD25–	cells	were	used	
as	internal	negative	controls,	since	these	cells	are	FoxP3–,	as	shown	in	(Figure	3.2	d).	It	is	





















































































panels,	and	 lymphocytes	and	monocytes	 for	myeloid	panel.	 (b)	Single	cells	were	 then	






































In	 order	 to	 minimise	 variation	 in	 immune-phenotyping	 panels	 and	 reduce	 the	 time	










could	be	effectively	discriminated	with	different	 concentrations	of	 dye	 (Figure	3.5	 a).	
However,	when	 combined	with	 other	 staining	 panels,	 although	 CD4+	 T	 cells	 could	 be	












Following	 lymphocyte	 +	 monocyte	 gating	 as	 in	 Figure	 3.1	 a:	 (a)	 classical	 monocytes	




















(a)	 PBMCs	 from	 different	 healthy	 control	 donors	 were	 labelled	 with	 indicated	












(CS&T)	 beads	 were	 used	 during	 acquisition.	 CS&T	 beads	 are	 composed	 of	 equal	
concentrations	of	dim,	mid,	and	brightly	dyed	polystyrene	beads	which,	critically,	have	
low	intrinsic	coefficients	of	variation.	These	beads	are	used	to	set	baseline	‘target’	laser	




frozen	 down	 into	 multiple	 aliquots	 and	 was	 run	 with	 every	 clinical	 trial	 sample	 and	
analysed	 in	parallel	with	trial	samples	 in	every	run	(Figure	3.6	a	and	b).	Coefficient	of	
variation	 (CV)	was	 calculated	 for	 both	MFI	of	 functional	markers	 in	myeloid	 cells	 and	
percentages	 of	 gated	 populations	 (Table	 3.2).	 Most	 measures	 showed	 low	 variation	









trial.	 On	 thawing,	 19	 of	 these	 patient	 samples	 were	 deemed	 to	 have	 useable	 PBMC	
samples	both	before	and	after	 repletion	 for	 flow	cytometry	analysis	 (defined	as	>20%	
lymphocytes	and	monocytes	gated	using	FSC-A	and	SSC-A)	 (Figure	3.7).	Nine	of	 these	









(b)	 form	multiple	 aliquots	 of	 a	 single	 healthy	donor	 run	 in	 parallel	with	 every	 pair	 of	











mDC	 CD14+/CD16+	 CD14+/CD16-	 	 mDC	 CD14+/CD16+	 CD14+/CD16-	 	 mDC	 CD14+/CD16+	 CD14+/CD16-	
46.42	 69.13	 49.10	 	 19.51	 14.15	 14.10	 	 28.44	 68.15	 39.35	
	
mDC(%)	 CD14+/CD16+(%)	 CD14+/CD16-	(%)	 B-cells	(%)	 NK	cells	(%)	 NKcells/CD56Bright	(%)	 NKcells/CD56Dim	(%)	 CD4	(%)	 CD8	(%)	 gd	T	Cells	(%)	
11.72	 27.50	 7.94	 18.29	 18.48	 27.18	 1.05	 9.55	 14.96	 41.16	
	
CD4+CD45RA+	(%)	 CD4+CD45RO+	(%)	 Treg	(%)	 TReg/FoxP3+	(%)	























Representative	 flow	 cytometry	 plots	 of	 PBMC	 sample	 deemed	 useable	 (a)	 and	 not	



























Within	 the	 CD4+	 T	 cell	 compartment,	 no	 significant	 changes	 were	 seen	 in	
percentages	of	naïve,	memory	T	 cells	nor	Tregs	 (Figure	3.9	a	and	b).	Additionally,	no	
significant	changes	in	FoxP3+	percentage	were	seen	(Figure	3.9	b).	No	significant	changes	
were	 observed	 in	 percentages	 of	 any	 of	 the	 major	 leukocyte	 populations	 measured	
(Figure	 3.10).	 Finally	 no	 significant	 changes	were	 seen	 in	 percentages	 of	 CD14+CD16+	
(Figure	 3.11	 a)	 or	 CD14+CD16-	 monocyte	 populations	 (Figure	 3.12	 a),	 nor	 in	 their	
expression	of	CD80,	CD86	and	HLA-DR	(Figure	3.11	b	and	Figure	3.12	b).	
We	 noted	 a	 significant	 treatment	 x	 week	 interaction	 between	 cholecalciferol	
supplementation	and	VitD	 levels	 (Figure	3.13	a)	as	well	as	HLA-DR	MFI	expression	on	
mDCs	(Figure	3.13	b).	However,	there	were	no	significant	changes	in	actual	percentages	






HLA-DR	 expression	 in	 the	 cholecalciferol-treated	 group,	 which	 was	 not	 seen	 in	 the	
placebo	 group	 (p=0.0106,	 t=3.214)	 (Figure	 3.14	 b).	 Although	 levels	 of	 serum	 25	 VitD	
increased	after	treatment,	levels	reached	a	mean	of	71.2	nM,	still	below	the	threshold	at	
which	VitD	sufficiency	is	classified	(>75nM).	Not	all	25	VitD	levels	were	available	for	both	
time-points	 (Figure	 3.13	 a),	 which	may	 reduce	 the	magnitude	 of	 change	 seen	 in	 the	
overall	study	population.	
In	 summary,	 serum	 levels	 of	 25	 VitD	 significantly	 increased	 and	 HLA-DR	
expression	on	mDCs	significantly	decreased	in	the	cholecalciferol	treatment	group	but	




low	HLA-DR	expression	(Lyons et al., 2010; Marchal et al.),	this	effect	is	an	indication	

























































absence	 of	 VitD	 by	 high	 expression	 of	 HLA-DR,	 CD80	 and	 CD86	 (Figure	 3.15).	 VitD	
significantly	inhibited	this	maturation	of	DCs	by	inhibiting	expression	of	CD80,	CD86	and	
HLA-DR	during	the	maturation	process	(Figure	3.15).	This	confirmed	the	published	data	
(Lyons et al., 2010; Marchal et al.)	and	our	clinical	trial	data,	that	VitD	can	inhibit	the	















profiling	 testing	 the	 effect	 of	 VitD	 supplementation	 on	 circulating	 immune	 cell	
frequencies	in	a	randomised,	double	blinded	clinical	trial	setting.	We	have	carried	out	a	
comprehensive	 analysis	 of	 the	 main	 immune	 cell	 subsets	 before	 and	 after	 VitD	
supplementation	in	a	cohort	of	patients	with	early	stage	CKD	and	early	CVD.	The	major	
findings	 of	 this	 chapter	 are	 that	 supplementation,	 in	 patients	 with	 early	 CKD,	 using	




to	 reduce	HLA-DR	 expression	 (Marchal et al.; Mora et al., 2008),	 an	 effect	 further	
confirmed	in	vitro	in	this	chapter.	This	effect	,along	with	reducing	other	co-stimulatory	
molecules	 (such	 as	 CD80	 and	 D86),	 has	 been	 suggested	 to	 be	 one	 of	 the	 major	
immunoregulatory	 mechanism	 by	 which	 VitD	 indirectly	 leads	 to	 Treg	 generation	
(Chambers	 and	 Hawrylowicz,	 2011).	 Lower	 HLA-DR	 expression	 is	 associated	 with	 an	
immature	DC	phenotype	and	a	reduced	ability	to	provide	the	co-stimulation	required	for	
appropriate	effector	T	cell	responses,	preferentially	generating	Tregs	instead	(Adorini	and	
Penna,	 2009).	 Additionally,	 an	 activated	 mDC	 phenotype	 (notably	 increased	 HLA-DR	


















reflect	 the	 non-inflamed	 nature	 of	 our	 cohort.	 In	 fact,	 a	 recent	 meta-analysis	 of	
cholecalciferol	 treatment	on	 the	 systemic	 inflammatory	profile	 in	adults	 free	of	acute	







Interestingly,	 we	 also	 did	 not	 observe	 a	 significant	 change	 in	 immune	 cell	









major	white	 blood	 cell	 populations	 in	 CKD	 populations	 compared	 to	 healthy	 controls	
(Litjens	 et	 al.,	 2006),	 whilst	 others	 have	 observed	 differences	 in	 functional	 markers	
(Girndt	 et	 al.,	 2001;	 Sui	 et	 al.,	 2009).	 Specifically,	 VitD	 deficiency	 and	 increased	
frequencies	of	CD4+CD28null	cells	in	CKD	patients	have	been	correlated	with	accelerated	
atherosclerosis	 (Yadav	 et	 al.,	 2012).	 CD4+CD28null	 T	 cells	 are	 a	 subset	 of	 helper	 T	
lymphocytes	 that	 are	 potential	 catalysts	 of	 inflammation	 in	 several	 inflammatory	
		
101	
disorders	 (Dumitriu,	2015).	Thus,	perhaps	 future	 trials	 should	 include	more	 functional	
markers	 of	 VitD	 induced	 immuno-regulation	 rather	 than	 focusing	 on	 frequencies	 of	
circulating	populations.	 Indeed,	 in	this	chapter	HLA-DR	expression	on	subsets	was	one	














section	2.1.1	and	Table	2.1).	 This	 regimen	was	 chosen	as	 similar	 regimens	have	been	
proven	 safe	 and	 effective	 at	 increasing	 levels	 of	 25	 VitD	 from	 <50nmol	 to	 >75	 nM	
(Chandra	 et	 al.,	 2008)	 in	 CKD	 patients.	 However,	 in	 this	 trial,	 although	 a	 significant	
increase	 in	 25	 VitD	 levels	 was	 seen,	 repletion	 above	 75nM	 was	 only	 obtained	 in	 2	
participants	 receiving	 cholecalciferol.	 This	 may	 have	 been	 due	 to	 the	 differences	 in	
dosing.	In	the	original	trial	50,000	IU	was	given	once	a	week	for	12	weeks.	To	make	the	











Although	we	 do	 not	 currently	 have	 access	 to	 the	 clinical	 data	 (the	 trial	 is	 still	






showed	 cholecaciferol	 repletion	 of	 stage	 5	 CKD	 and	 haemodialysis	 patients	 led	 to	















analysis	 of	 28	 high	 quality	 randomised	 control	 trials	 (RCTs)	 and	 observational	 studies	
(OSs)	 with	 over	 220,000	 CKD	 patients,	 showed	 no	 significant	 benefit	 in	 RCTs	 of	 VitD	
treatment	in	all-cause	mortality	or	cardiovascular	mortalities.	However,	this	contrasted	
with	OSs	in	which	VitD	treatment	was	significantly	associated	with	reductions	in	all-cause	






















Although	no	differences	were	observed	in	CD4+	T	cells	 in	the	clinical	trial	 it	 is	known	




(Dankers	et	al.,	 2016).	However,	 the	mechanisms	by	which	VitD,	 through	binding	 to	
VDR,	 influences	cytokine	production	are	poorly	understood,	particularly	 in	T	cells.	 In	
fact	 no	publications	 have	 suggested	 a	mechanism	by	which	 vitamin	D	 induces	 IL-10	
production	from	CD4+	T	cells,	with	one	study	identifying	a	VDR	binding	site	upstream	of	
the	 IL-10	promoter	as	a	mechanism	 for	VitD	 induced	 IL-10	production	 in	monocytes	
(Matilainen	et	al.,	2010).	Only	one	study	has	 investigated	genome-wide	VDR	binding	
locations	in	CD4+	T	cells	(Handel	et	al.,	2013)	and	did	not	treat	the	cells	with	active	1,25	












cells	was	 dependent	 on	 decreased	NFAT	 binding	 upstream	 of	 the	 IL-17	 tss	 through	
recruitment	of	HDACs	and	reduced	H4	acetylation	(Joshi	et	al.,	2011).	




phenotype.	 To	date,	 the	bulk	of	 evidence	points	 towards	histone	acetylation	 as	 the	
primary	epigenetic	effect	of	VitD,	with	only	a	few	studies	suggesting	VitD	may	also	affect	
DNA	methylation	(Fetahu	et	al.,	2014;	Nemere	et	al.,	1998).	This	is	likely	one	of	the	key	









in	 relation	 to	 the	 physiological	 actions	 of	 VitD	 in	 a	 given	 cell	 environment	 several	
parallel	approaches	should	be	gainfully	employed,	notably:	1)	Monitoring	of	genomic	
VDR	loci	by	ChIP-seq	2)	genome	wide	assessment	of	chromatin	accessibility	ChIP-seq	















b) Studying	 the	 mechanisms	 underlying	 VitD	 induced	 IL-10	 production,	













As	previously	reported	(Kongsbak et al., 2014),	VDR	was	not	expressed	in	un-
activated	 CD4+	 T	 cells	 but	 induced	 after	 activation	 at	 both	mRNA	 (Figure	 4.1	 a)	 and	
protein	level	(Figure	4.1	b).	VDR	protein	expression	progressively	increased	over	time	
with	both	carrier-	and	VitD-treatment,	but	the	presence	of	VitD	significantly	increased	
VDR	 protein	 expression	 relative	 to	 carrier	 alone	 (Figure	 4.1	 b).	 As	 with	 protein	
expression,	T	cell	activation	induced	VDR	mRNA	expression	in	a	manner	also	augmented	
by	the	presence	of	VitD	(Figure	4.1	a).	Collectively,	these	data	demonstrate	that	T	cell	






















































VitD	 significantly	 decreased	 concentrations	 of	 IFNg	 and	 reduced	 IL-17	
concentrations	 in	culture	supernatants,	whilst	having	no	effect	on	 IL-4,	TNF-a	or	 IL-2	
(Figure	4.3	b).	At	the	same	time,	there	was	a	substantial	increase	in	concentrations	of	IL-
10	in	culture	supernatants	(Figure	4.3	b).	We	were	surprised	to	observe	substantial	and	
significantly	 increased	 concentrations	 of	 IL-6	 in	 VitD-treated	 culture	 supernatants	
(Figure	4.3	b).		
IL-6	is	a	cytokine	not	normally	associated	with	T	cells.	To	confirm	this	observation	




as	1	day	of	culture,	and	 IL-6	protein	as	early	as	3	days	 (Figure	4.3	c).	 In	addition,	we	
performed	intracellular	staining	for	IL-6	and	found	a	greater	percentage	of	CD4+	T	cells	











Cytokine	 concentrations	 in	 supernatants	 of	 T	 cell	 cultures	 after	 5	 days	 of	 polyclonal	
activation	with	carrier	or	VitD;	(c)	IL6	mRNA,	fold	change	compared	to	day	1	carrier	(left)	
and	 IL-6	protein	 concentration	 in	matched	 supernatants	 (right)	 at	 days	 1,	 3	 and	5	 in	
carrier	 and	 VitD	 treated	 cultures;	 (d)	 Representative	 flow	 cytometry	 plot	 (left)	 and	
cumulative	data	(right)	of	intracellular	IL-6	expression	in	T	cells	treated	with	carrier	or	
VitD	(assay	carried	out	on	day	3).	Bar	graphs	show	cumulative	data	(mean	±	SEM).	All	













VitD	 has	 been	 reported	 to	 act	 directly	 on	 T	 cells	 to	 induce	 a	 Treg	 phenotype	
(Chambers	 and	 Hawrylowicz,	 2011).	 Since	 we	 saw	 suppression	 of	 IFN-g	 and	 IL-17	 in	
culture	supernatants	and	enhanced	 IL-10,	we	next	assessed	 the	phenotype	of	CD4+	T	
cells	activated	in	the	presence	of	VitD	to	determine	whether	we	had	generated	induced	



























































with	maximal	 effect	 on	 IL-6	 and	 IL-10	 at	 1	 to	 10nM	 and	maximal	 inhibition	 of	 IFNg	
occurring	at	100nM	(Figure	4.5	a).	Interestingly	at	higher	concentrations	(50-100nM)	of	
VitD	both	the	IL-6	and	IL-10	response	decreased,	whereas	the	IFNg		response	reduced	at	
each	 increase	 VitD	 dose	 (Figure	 4.5	 a).	 Since	 both	 IL-10	 and	 IL-6	 showed	 an	 almost	
identical	 response	 to	 activation	 in	 the	 presence	 of	 VitD,	 and	 were	 strongly	 linearly	





both	carrier	and	VitD-treated	conditions	 there	was	an	 initial	drop	 in	 IL-6R	expression	
from	 baseline,	 which	 gradually	 returned	 to	 baseline	 over	 5	 days	 (Figure	 4.5	 c).	
Intriguingly,	IL-6R	expression	in	VitD-treated	cells	was	lower	in	VitD-treated	cells,	after	5	
days,	 compared	 to	 carrier	 alone,	 as	 might	 be	 expected	 if	 the	 receptor	 is	 shed	 or	
internalised	 following	 receptor-ligand	 interaction	 (Figure	 4.5	 c).	 IL-10R	 expression,	 in	






and	 in	 trans	 	 (Mihara	 et	 al.,	 2011).	 When	 IL-6	 signalling	 was	 blocked,	 at	 each	
concentration	of	VitD,	 IL-10	production	was	also	significantly	 inhibited	 (Figure	4.7	a),	




VitD	 did	 not	 induce	 the	 production	 of	 IL-10	 from	 carrier	 treated	 cells	 (Figure	 4.7	 b),	
suggesting	that	the	concurrent	presence	of	VitD	is	a	requisite.	Addition	of	IL-6	to	cultures	

















mean	±	 SEM	 throughout;	 (n	=	3	 independent	experiments	 for	 each	panel,	 compared	


































response	 to	 VitD.	 We	 found	 that	 memory	 T	 cells	 were	 the	 dominant	 population	
producing	IL-10	in	response	to	VitD	and	that	the	pattern	of	cytokine	secretion	was	similar	
to	 that	 observed	 in	 bulk	 CD4+	 T	 cells	 –	 IL-6	 and	 IL-10	 were	 induced	 together,	 with	





this	 effect	 was	 mirrored	 but	 again	 at	 much	 lower	 concentration	 (Figure	 4.8	 b).	
Interestingly,	measurement	of	cytokines	in	naïve	CD4+	T	cells	was	restricted	to	day	3,	as	
at	day	5	substantial	cell	death	was	observed	in	the	wells.	Since	the	effect	of	VitD	was	










in	 human	CD4+	 T	 cells	 also	 exists	 in	mouse	CD4+	 T	 cells.	 CD4+	 T	 cells	 from	wild	 type	
C56Bl/6	(B6)	mice	were	polyclonally	activated	with	aCD3/CD28	in	the	presence	of	VitD	
or	carrier	and	supernatants	assessed	for	cytokine	concentrations.	While	we	observed	a	










Figure	 4.8|VitD	 effect	 on	 cytokine	 production	 from	memory	 and	 naïve	 CD4+	 T	 cell	
compartments|	
Cytokine	 concentrations	 in	 supernatants	 of	 activated	 FACS-sorted	 memory	 (CD25-
CD45RA-CD45RO+)	(a)	and	naïve	(CD25-CD45RA+CD45RO-)	(b)	CD4+	T	cells	at	day	3	and	5	
in	 the	 presence	 of	 carrier,	 VitD	 and	 VitD	 plus	 Toc.	 Bar	 graphs	 show	 mean	 ±	 SEM	




















CYP27B1	 and	 convert	 25	 VitD	 to	 1,25	 VitD	 (Correale et al., 2009; Kongsbak and 




absence	 of	 25	 VitD	 (25(OH)VitD),	 at	 physiological	 concentrations,	 with	 and	 without	
activation	 through	 CD3/CD28.	 We	 observed	 that	 production	 of	 both	 IL-6	 and	 IL-10	
occurred	 with	 25	 VitD	 in	 the	 same	manner	 as	 with	 the	 active	 form	 of	 the	 vitamin,	
although	only	in	activated	memory	CD4+	T	cells	(Figure	4.10	a).	Additionally,	IFNg	and	IL-
17	were	 both	 significantly	 inhibited	 in	 a	 dose	 dependent	manner	 in	 the	 presence	 of	
25(OH)D3	(Figure	4.10	b),	with	little	effect	seen	on	IL-4,	IL-2	and	TNFa	(Figure	4.10	c).	












Concentrations	 of	 (a)	 IL10,	 IL-6	 (b)	 IL-17	 IFNg	 and	 (c)	 IL-4	 IL-2	 and	 TNFa	 in	 culture	
supernatants	of	T	cells	activated	(black	circles)	or	not	(turquoise	squares)	in	the	presence	
of	escalating	doses	of	25(OH)VitD.	Line	graphs	show	mean	±	SEM.	(n	=	3	independent	
experiments;	 comparisons	made	using	 2-way	ANOVA	and	 follow	up	 t-tests;	 *p<0.05,	





4.4 Signalling	 and	 genomic	mechanisms	driving	 IL-6,	 IL-10	 signalling	 loop	 in	
memory	CD4+	T	cells	
We	have	thus	far	identified	a	novel	mechanism	underlying	VitD	induced	IL-10	production	





We	 sought	 to	 determine	 the	 downstream	 signals	 responsible	 for	 driving	 IL-10	
production.	 We	 initially	 carried	 out	 a	 phospho(p)-kinase	 antibody	 array	 for	 43	
phosphorylated	signalling	proteins	on	lysates	of	cells	activated	in	the	presence	of	active	
VitD	 (Figure	 4.11	a	and	b,	 and	Appendix	 1	 and	 Appendix	 2).	Of	 the	 phosphorylated	
proteins	 assayed,	 phosphorylated	 pS63-c-Jun,	 pY705-STAT3,	 pT183/pY185,	
pT221/pY223-Jnk-1/2/3	 and	pT183-AMPKa1	were	 consistently	 increased	 and	pHsp60	







more	 STAT3	 phosphorylation	 or	 simply	 more	 STAT3	 in	 VitD	 treated	 cells,	 we	
immunoblotted	for	total	and	pY705-STAT3	(hereafter	simply	called	pSTAT3)	in	lysates	of	
VitD	treated	cells.	Although	low	level	phosphorylation	of	STAT3	was	evident	at	3	days	
following	 TCR	 activation	 in	 isolation,	 addition	 of	 VitD	 significantly	 increased	 pSTAT3	
(Figure	 4.12	 a	 and	 b).	 Additionally,	 total	 STAT3	 protein	 was	 significantly	 induced	 in	
presence	of	VitD	(Figure	4.12	a	and	b),	suggesting	that	the	observed	increased	pSTAT3	
is	at	 least	 in	part	due	 to	 increased	 total	 STAT3	expression	 induced	by	VitD.	With	 the	







These	 findings	 contrasted	 with	 phosphorylation	 of	 c-Jun	 which,	 though	 significantly	
increased	 in	 the	 presence	 of	 VitD,	 was	 sustained	 in	 the	 presence	 of	 IL-6R	 blockade	
(Figure	 4.12	 a	 and	 b),	 suggesting	 that	 IL-6	 binding	 to	 IL-6R	 does	 not	 lead	 to	








in	 STAT3-silenced	 T	 cells	 (Figure	 4.13	 b).	 Interestingly,	 an	 increase	 in	 IL-6	 was	 also	
observed	(Figure	4.13	b).	We	confirmed	approximately	50%	knockdown	of	total	STAT3	
was	achieved	using	 shRNA	 (Figure	4.13	 c	and	d).	 These	effects	were	mirrored	 in	 the	
pSTAT3	levels.	




















Figure	 4.12|STAT3	 but	 not	 c-Jun	 is	 directly	 phosphorylated	 as	 response	 to	 IL6R	
engagement|	
(a)	Western	blot	of	polyclonally	activated	memory	CD4+	T	cells,	in	the	presence	of	carrier	
or	 VitD	 with	 and	 without	 Toc	 at	 the	 concentrations	 shown.	 Western	 blot	 for	
phosphorylated	and	total	c-Jun	as	well	as	phosphorylated	and	total	STAT3	with	Hsp90	as	
loading	control.	Representative	image	(a)	and	quantification	of	cumulative	data	(b).	All	
























has	 been	 shown	 to	 affect	 gene	 regulation	 through	 recruitment	 of	 a	 diverse	 set	 of	
transcriptional	machinery,	 primarily	 altering	histone	modifications	 (see	 section	1.3.3)	
(Fetahu	et	al.,	2014),	it	followed	that	the	mechanism	underlying	the	observed	signaling	
loop	could	be	epigenetic	modifications	induced	by	VitD.	Thus,	to	delineate	the	molecular	








CYP24A1	 gene	 for	 possible	 RXR/VDR	 binding	 motifs	 using	 JASPAR	 motif	 scanning	
(Mathelier	et	al.,	2014)	for	the	VDR/RXR	motif	shown	in	(Figure	4.14	a).	The	prediction	
successfully	identified	the	canonical	VDRE	elements	VDREp	and	VDREd.	(Figure	4.12	b).	

















conservation	 of	 genomic	 sequence	 between	 all	 mammalian	 species	 with	 sequenced	
genomes.	A	positive	 value	on	 the	histogram	 represents	positive	enrichment	which	 is	


























broader	 enrichment	 compared	 to	H3K4me3,	 as	 expected.	 To	 confirm	 these	 results	 a	
principle	component	analysis	was	carried	out	on	all	ChIP-seq	samples	from	both	donors.	
Both	 native	 and	 cross-linked	 inputs	 controls	 clustered	 together	 with	 VDR	 ChIP-seq	



















are	sorted	according	 to	 their	 rank	 (the	bin	with	 the	highest	number	of	 reads	has	 the	
highest	rank),	with	the	cumulative	sum	plotted.	(d)	Principle	component	analysis	(PCA)	
with	 all	 conditions	 and	donors	 combined.	H3K4me3	 cluster	 indicated	by	orange	box,	
H3K27Ac	clusters	indicated	by	blue	box	and	VDR	and	input	clusters	indicated	by	black	










This	 indicates	 good	 reproducibility	 of	 peak	 identification	 between	 two	 biological	
replicates.	Within	the	common	H3K4me3	peaks,	a	strong	correlation	was	identified	in	
ChIP-seq	 signal,	 in	 both	 carrier	 and	 VitD	 treatment	 conditions	 (Figure	 4.16	 b)	 and	
unsupervised	 clustering	 of	 ChIP-seq	 signal	 showed	 very	 similar	 cluster	 formation	
between	both	donors	and	treatments	(Figure	4.16	b).	For	H3K27Ac	a	good	correlation	
was	also	observed	 in	ChIP-seq	signal	 from	peaks	 in	common	between	donors	 in	VitD	
treated	cells	(Figure	4.16	d).	A	 lower	correlation	was	observed	in	carrier	treated	cells	


























VitD	 treatment	 alters	 the	 overall	 distribution	 of	 H3K27Ac	 peaks	 in	 the	 genome.	 The	
genome,	as	a	whole,	consists	of	predominantly	distal	intergenic	regions,	which	have	no	
assigned	 function	 in	our	analysis,	with	 the	majority	of	 the	 rest	being	 intronic	 regions	
(Figure	4.17	a).	Most	H3K27Ac	peaks	 in	our	ChIP-seqs	were	 located	within	 introns	of	
genes,	with	increased	localisation	to	promoters	compared	to	genomic	background,	but	








b	 and	 c).	We	 analysed	 the	 DNA	 sequences	 corresponding	 to	 induced	 and	 repressed	




TF	motifs	were	 those	of	AP1	 family	members,	 including	 Jun	 (Table	4.1).	 The	 Jun-AP1	












VitD	 stimulated	 lymphoblastoid	 cell	 line	 (LCL)	 (GSM558636).	 Additionally,	 as	 VDR	
recruits	histone	acetylases	(HATs),	such	as	p300	(Haussler et al., 2011; 2013),	we	also	


























are	 shown	 with	 RPKM	 normalisation	 in	 black	 and	 RPGC	 normalisation	 in	 grey.	
Highlighted	in	box	are	locations	of	IL6	(black)	and	STAT3	(orange)	putative	enhancers.	








	 	 	 	 Target	sequences	with	Motif	 Background	sequences	with	Motif	 	
Motif	name	 Consensus	 P-value	 q-value	 Number	 %	 Number	 %	 Motif	enrichment	(fold)	
VDR(NR),DR3	 ARAGGTCANWGAGTTCANNN	 1.00E-45	 0	 303	 34.99%	 7469.5	 15.25%	 2.29	
Fosl2(bZIP)	 NATGASTCABNN	 1.00E-35	 0	 322	 37.18%	 9240.8	 18.87%	 1.97	
Fra1(bZIP)	 NNATGASTCATH	 1.00E-33	 0	 443	 51.15%	 15287.4	 31.22%	 1.64	
Atf3(bZIP)	 DATGASTCATHN	 1.00E-32	 0	 487	 56.24%	 17774.5	 36.29%	 1.55	
BATF(bZIP)	 DATGASTCAT	 1.00E-31	 0	 479	 55.31%	 17434.6	 35.60%	 1.55	
Jun-AP1(bZIP)	 GATGASTCATCN	 1.00E-31	 0	 248	 28.64%	 6555.2	 13.39%	 2.14	
AP-1(bZIP)	 VTGACTCATC	 1.00E-25	 0	 499	 57.62%	 19557.1	 39.93%	 1.44	
Bach2(bZIP)	 TGCTGAGTCA	 1.00E-12	 0	 173	 19.98%	 5630	 11.50%	 1.74	
Ets1-distal(ETS)	 MACAGGAAGT	 1.00E-07	 0	 241	 27.83%	 9893.3	 20.20%	 1.38	
bZIP:IRF(bZIP,IRF)	 NAGTTTCABTHTGACTNW	 1.00E-06	 0	 310	 35.80%	 13588.9	 27.75%	 1.29	
Bach1(bZIP)	 AWWNTGCTGAGTCAT	 1.00E-05	 0.0001	 52	 6.00%	 1486.7	 3.04%	 1.97	
EWS:FLI1-fusion(ETS)	 VACAGGAAAT	 1.00E-04	 0.0003	 362	 41.80%	 17020.7	 34.76%	 1.20	
MafK(bZIP)	 GCTGASTCAGCA	 1.00E-04	 0.0005	 153	 17.67%	 6252.8	 12.77%	 1.38	
NF-E2(bZIP)	 GATGACTCAGCA	 1.00E-04	 0.0008	 50	 5.77%	 1528.5	 3.12%	 1.85	
IRF:BATF(IRF:bZIP)	 CTTTCANTATGACTV	 1.00E-04	 0.0008	 109	 12.59%	 4182.7	 8.54%	 1.47	
SpiB(ETS)	 AAAGRGGAAGTG	 1.00E-04	 0.001	 193	 22.29%	 8364.5	 17.08%	 1.31	
ETS1(ETS)	 ACAGGAAGTG	 1.00E-04	 0.0012	 551	 63.63%	 27993.8	 57.16%	 1.11	
PU.1(ETS)	 AGAGGAAGTG	 1.00E-04	 0.0014	 335	 38.68%	 15930.9	 32.53%	 1.19	
ETS:RUNX(ETS,Runt)	 RCAGGATGTGGT	 1.00E-03	 0.0024	 87	 10.05%	 3289.7	 6.72%	 1.50	





	 	 	 	 Target	sequences	with	Motif	 Background	sequences	with	Motif	 	
Motif	Name	 Consensus	 P-value	 q-value	 Number	 %	 Number	 %	 Motif	enrichment	(fold)	
Jun-AP1(bZIP)	 GATGASTCATCN	 1.00E-40	 0	 225	 31.08%	 6018.1	 12.23%	 2.54	
Fosl2(bZIP)	 NATGASTCABNN	 1.00E-39	 0	 284	 39.23%	 8891.5	 18.07%	 2.17	
IRF2(IRF)	 GAAASYGAAASY	 1.00E-38	 0	 183	 25.28%	 4297.6	 8.73%	 2.90	
IRF1(IRF)	 GAAAGTGAAAGT	 1.00E-35	 0	 227	 31.35%	 6507.9	 13.23%	 2.37	
ISRE(IRF)	 AGTTTCASTTTC	 1.00E-35	 0	 136	 18.78%	 2705.5	 5.50%	 3.41	
Fra1(bZIP)	 NNATGASTCATH	 1.00E-33	 0	 427	 58.98%	 18039.2	 36.66%	 1.61	
BATF(bZIP)	 DATGASTCAT	 1.00E-28	 0	 447	 61.74%	 20191.6	 41.04%	 1.50	
bZIP:IRF(bZIP,IRF)	 NAGTTTCABTHTGACTNW	 1.00E-28	 0	 441	 60.91%	 19834.8	 40.31%	 1.51	
AP-1(bZIP)	 VTGACTCATC	 1.00E-26	 0	 460	 63.54%	 21372.9	 43.44%	 1.46	
Atf3(bZIP)	 DATGASTCATHN	 1.00E-26	 0	 442	 61.05%	 20268.5	 41.19%	 1.48	
Bach2(bZIP)	 TGCTGAGTCA	 1.00E-22	 0	 164	 22.65%	 4935.5	 10.03%	 2.26	
IRF4(IRF)	 ACTGAAACCA	 1.00E-17	 0	 357	 49.31%	 16531.2	 33.60%	 1.47	
ETS1(ETS)	 ACAGGAAGTG	 1.00E-17	 0	 467	 64.50%	 23930.6	 48.63%	 1.33	
Etv2(ETS)	 NNAYTTCCTGHN	 1.00E-15	 0	 452	 62.43%	 23289.2	 47.33%	 1.32	
Ets1-distal(ETS)	 MACAGGAAGT	 1.00E-13	 0	 219	 30.25%	 9075.3	 18.44%	 1.64	
EWS:FLI1-fusion(ETS)	 VACAGGAAAT	 1.00E-13	 0	 311	 42.96%	 14531	 29.53%	 1.45	
IRF:BATF(IRF:bZIP)	 CTTTCANTATGACTV	 1.00E-13	 0	 177	 24.45%	 6813	 13.85%	 1.77	
PU.1:IRF8(ETS:IRF)	 GGAAGTGAAAST	 1.00E-13	 0	 192	 26.52%	 7684.2	 15.62%	 1.70	






	 As	the	enhancer	sites	within	the	STAT3	 intron	and	upstream	of	the	 IL6	 tss	are	
putative	and	novel	we	confirmed	the	VitD	 induced	 induction	of	H3K27	acetylation	at	
these	sites	in	a	second	donor.	This	was	particularly	important	as	there	was	great	donor	
variability	 observed	 in	H3K27Ac	ChIP-seq	 signal	 in	 carrier	 treated	 conditions	 (section	
4.4.2.3).	Despite	this	donor	variability,	H3K27	acetyation	upstream	of	both	the	 IL6	tss	







(orange)	 putative	 enhancers,	 shown	 in	Donor1	 (Don1)	 at	 top	 and	Donor	 2	 (Don2)	 at	














identified	peaks,	and	3,667	peaks	 induced	(1.5	 fod	 increased	compared	to	carrier)	by	
VitD	treatment,	and	3,896	peaks	repressed	(1.5	fold	decreased	compared	to	carrier)		by	







was	 repressed	 by	 VitD	 (Figure	 4.19	 b).	 We	 again	 visualised	 tracks	 and	 aligned	 VDR	















HAT	 p300	 recruitment.	 Following	 phosphorylation	 of	 STAT3,	 through	 IL-6	 signalling,	

















(b)	 Intensity	 of	 H3K4me3	 signal	 in	 carrier	 treated	 compared	 to	 VitD	 treated	 cells	 in	
scatter	plot	(left).	Peaks	1.5	fold	induced	(blue	gate)	and	repressed	(red	gate)	by	VitD	
treatment	are	marked.	Location	of	IL-6	(black)	and	STAT3	(orange)	peaks	are	represented	




VitD	 treated	 lymphoblastoid	 cell	 line	 (LCL)	 in	 green	 and	 STAT3	 track	 from	 B	 cell	












carrier	 treated	 CD4+	 T	 cells,	 with	 VDR	 tracks	 from	 unstimulated	 and	 VitD	 treated	








	 	 	 	 Target	sequences	with	Motif	 Background	sequences	with	Motif	 	
Motif	name	 Consensus	 P-value	 q-value	 Number	 %	 Number	 %	 Motif	enrichment	(fold)	
CTCF(Zf)	 AYAGTGCCMYCTRGTGGCCA	 1.00E-123	 0	 964	 27.10%	 5214.1	 12.33%	 2.20	
BORIS(Zf)	 CNNBRGCGCCCCCTGSTGGC	 1.00E-80	 0	 1595	 44.84%	 12533.9	 29.64%	 1.51	
Sp1(Zf)	 GGCCCCGCCCCC	 1.00E-15	 0	 1741	 48.95%	 17847.7	 42.20%	 1.16	
E2F6(E2F)	 GGCGGGAARN	 1.00E-08	 0	 2233	 62.78%	 24526.7	 57.99%	 1.08	
E2F4(E2F)	 GGCGGGAAAH	 1.00E-06	 0	 1963	 55.19%	 21580.3	 51.03%	 1.08	
Klf9(Zf)	 GCCACRCCCACY	 1.00E-05	 0.0005	 1736	 48.81%	 19126	 45.22%	 1.08	
RFX(HTH)	 CGGTTGCCATGGCAAC	 1.00E-04	 0.0015	 310	 8.72%	 2936.3	 6.94%	 1.26	
Rfx2(HTH)	 GTTGCCATGGCAACM	 1.00E-04	 0.0031	 328	 9.22%	 3167.3	 7.49%	 1.23	
Jun-AP1(bZIP)	 GATGASTCATCN	 1.00E-04	 0.0031	 407	 11.44%	 4028.1	 9.52%	 1.20	
X-box(HTH)	 GGTTGCCATGGCAA	 1.00E-04	 0.0031	 285	 8.01%	 2707.6	 6.40%	 1.25	
Mef2c(MADS)	 DCYAAAAATAGM	 1.00E-03	 0.0051	 589	 16.56%	 6091.7	 14.40%	 1.15	
Fosl2(bZIP)	 NATGASTCABNN	 1.00E-03	 0.0078	 549	 15.43%	 5675.6	 13.42%	 1.15	
Mef2a(MADS)	 CYAAAAATAG	 1.00E-03	 0.0201	 613	 17.23%	 6467.3	 15.29%	 1.13	
Mef2b(MADS)	 GCTATTTTTGGM	 1.00E-03	 0.0216	 1067	 30.00%	 11688.8	 27.64%	 1.09	
HOXD13(Homeobox)	 NCYAATAAAA	 1.00E-02	 0.051	 1199	 33.71%	 13316.9	 31.49%	 1.07	
Lhx1(Homeobox)	 NNYTAATTAR	 1.00E-02	 0.0672	 1233	 34.66%	 13750.5	 32.51%	 1.07	
Bach2(bZIP)	 TGCTGAGTCA	 1.00E-02	 0.0672	 359	 10.09%	 3711.6	 8.78%	 1.15	
Fra1(bZIP)	 NNATGASTCATH	 1.00E-02	 0.0672	 767	 21.56%	 8347.8	 19.74%	 1.09	
E2F1(E2F)	 CWGGCGGGAA	 1.00E-02	 0.0761	 1349	 37.93%	 15143.7	 35.81%	 1.06	





	 	 	 	 Target	sequences	with	Motif	 Background	sequences	with	Motif	 	
Motif	name	 Consensus	 P-value	 q-value	 Number	 %	 Number	 %	 Motif	enrichment	(fold)	
IRF2(IRF)	 GAAASYGAAASY	 1.00E-298	 0	 1240	 35.57%	 5278.9	 11.54%	 3.082	
IRF1(IRF)	 GAAAGTGAAAGT	 1.00E-244	 0	 1454	 41.71%	 7990.8	 17.47%	 2.388	
ISRE(IRF)	 AGTTTCASTTTC	 1.00E-239	 0	 897	 25.73%	 3385.3	 7.40%	 3.477	
Ets1-distal(ETS)	 MACAGGAAGT	 1.00E-100	 0	 1430	 41.02%	 11245	 24.58%	 1.669	
PU.1:IRF8(ETS:IRF)	 GGAAGTGAAAST	 1.00E-83	 0	 1230	 35.28%	 9588.5	 20.96%	 1.683	
EWS:FLI1-fusion(ETS)	 VACAGGAAAT	 1.00E-70	 0	 1898	 54.45%	 18084.3	 39.53%	 1.377	
ETS(ETS)	 AACCGGAAGT	 1.00E-68	 0	 1062	 30.46%	 8320.8	 18.19%	 1.675	
Elk1(ETS)	 HACTTCCGGY	 1.00E-67	 0	 1493	 42.83%	 13220.8	 28.90%	 1.482	
GABPA(ETS)	 RACCGGAAGT	 1.00E-64	 0	 2327	 66.75%	 24009.9	 52.48%	 1.272	
Elk4(ETS)	 NRYTTCCGGY	 1.00E-60	 0	 1492	 42.80%	 13536.9	 29.59%	 1.446	
IRF4(IRF)	 ACTGAAACCA	 1.00E-53	 0	 1920	 55.08%	 19217.4	 42.00%	 1.311	
ELF1(ETS)	 AVCCGGAAGT	 1.00E-52	 0	 1337	 38.35%	 12106.6	 26.46%	 1.449	
bZIP:IRF(bZIP,IRF)	 NAGTTTCABTHTGACTNW	 1.00E-51	 0	 2129	 61.07%	 22099.7	 48.30%	 1.264	
Etv2(ETS)	 NNAYTTCCTGHN	 1.00E-47	 0	 2498	 71.66%	 27379.9	 59.84%	 1.198	
PU.1(ETS)	 AGAGGAAGTG	 1.00E-47	 0	 1726	 49.51%	 17123.6	 37.43%	 1.323	
Fli1(ETS)	 NRYTTCCGGH	 1.00E-44	 0	 2516	 72.17%	 27794	 60.75%	 1.188	
ETS1(ETS)	 ACAGGAAGTG	 1.00E-43	 0	 2550	 73.15%	 28364.6	 62.00%	 1.180	
IRF:BATF(IRF:bZIP)	 CTTTCANTATGACTV	 1.00E-43	 0	 931	 26.71%	 7916.3	 17.30%	 1.544	
ETV1(ETS)	 AACCGGAAGT	 1.00E-33	 0	 2771	 79.49%	 32214.5	 70.41%	 1.129	










present	within	 regions	 of	 both	 H3K4me3	 and	H3K27Ac	 (n	 =	 35,195).	We	 found	 that	
around	 half	 (1,455)	 of	 LCL	 VDR	 peaks	 lay	 within	 regions	 of	 H3K4me3	 and	 H3K27Ac	
(Figure	 4.21	 a).	 The	 vast	 majority	 of	 these	 1,455	 VDR	 peaks	 (1,289)	 were	 correctly	
identified	as	VDR	motifs	(Figure	4.21	b)	validating	our	data.		
Having	 identified	 histone	 modifications	 at	 putative	 enhancer	 sites	 we	 next	




with	 only	 549	 localising	 to	 active	 promoters	 (Figure	 4.21	 c).	 This	 suggests	 that	 VDR	



























































Significant	 terms	 are	 hierarchically	 clustered	 into	 a	 tree	 based	 on	 Kappa-statistical	
similarities	among	their	gene	memberships.	The	heatmap	cells	are	coloured	by	their	p-








or	 repressed	 H3K27Ac.	 Encouragingly	 very	 few	 (<15)	 VitD	 induced	 and	 repressed	
H3K27Ac	peaks	were	concurrently	assigned	to	the	same	gene	(Figure	4.23	a).	Many	more	
genes	 with	 VDR	 motifs	 showed	 increased,	 rather	 than	 repressed,	 H3K27Ac	 signal	
following	VitD	treatment	(Figure	4.23	a),	consistent	with	data	from	section	4.4.2.3.1	in	
which	 we	 identified	 VDR	 as	 the	 most	 significantly	 enriched	 motif	 in	 H3K27Ac	 VitD	
induced	 peaks.	Most	 of	 the	 top	 20	 significantly	 enriched	 pathways	were	 not	 shared	
between	induced	and	repressed	gene	lists,	indicating	differential	acetylation	of	genes	in	
specific	pathways	 induced	by	VitD	 (Figure	4.23	b).	The	“IFNg	 response”	pathway	was	
identified	as	 statistically	enriched	 in	H3K27Ac	VitD	 repressed	gene	 list.	We	 therefore	
visualised	the	ChIP-seq	signal	at	each	of	the	regions	annotated	to	genes	identified	in	this	
pathway.	Dramatic	decrease	 in	 signal	was	observed	at	 each	of	 the	 regions	with	VitD	
treatment	(Figure	4.23	d).	The	“IL-6	Jak	STAT3	signalling”	pathway	was	also	statistically	
enriched	within	H3K27Ac	VitD	induced	genes	and	genes	contributing	to	this	pathway,	


























arc.	 Dark	 orange	 colour	 represents	 the	 genes	 that	 appear	 in	multiple	 lists	 and	 light	
orange	colour	represents	genes	that	are	unique	to	that	gene	list.	Purple	lines	link	the	
same	 gene	 that	 are	 shared	 by	multiple	 gene	 lists.	 Blue	 lines	 link	 the	 different	 genes	
where	 they	 fall	 into	 the	 same	 ontology	 term	 (all	 terms	 are	 statistically	 significantly	
enriched).	(b)	Heatmap	of	statistically	significant	pathways	from	H3K27Ac	induced	and	
H3K27Ac	repressed	gene	lists.	Significant	terms	are	hierarchically	clustered	into	a	tree	
based	 on	 Kappa-statistical	 similarities	 among	 their	 gene	memberships.	 The	 heatmap	
cells	are	coloured	by	their	p-values.	The	term	with	the	lowes	p-value	within	each	cluster	
was	 chosen	 as	 its	 representative	 term	 and	 display	 in	 a	 dendrogram	 with	 colours	




score	 >	 0.3	 are	 linked	 by	 an	 edge	 with	 the	 thickness	 of	 the	 edge	 representing	 the	
similarity	 score.	 (d)	 Heatmaps	 showing	 quantile	 normalised	H3K27Ac	 ChIP-seq	 signal	
from	carrier	and	VitD	treated	CD4+	T	cells	of	genes	within	pathways	from	(b)	and	(c),	








H3K27	 acetylation	with	 VDR	motifs,	was	 the	 T	 cell	 activation	 pathway	 (p=1.25x10-9),	
which	 represents	a	key	pathway	 in	our	experimental	 context.	 Significant	 increases	 in	
H3K27Ac	signal	after	treatment	with	VitD	in	all	43	members	of	this	pathway	were	evident	
(Figure	 4.24	 a),	 including	 some	of	 the	 genes	 encoding	 the	 key	 proteins	 differentially	
regulated	 in	 our	 study:	 IL6,	 IL10	 and	 STAT3	 (Figure	 4.24	 a).	 As	 discussed	 in	 section	
























from	two	donors	 (Donor	1,	Don1;	Donor	2,	Don2)	 in	VitD	treated	and	carrier	 treated	
CD4+	T	cells,	with	VDR	tracks	from	unstimulated	and	VitD	treated	lymphoblastoid	cell	
line	(LCL)	in	green.	Tracks	heights	are	shown	with	RPKM	normalisation	in	black	and	RPGC	








gene	 lists	 (Figure	 4.25	 a).	 Again,	 the	 majority	 of	 the	 top	 20	 significantly	 enriched	
pathways	 were	 not	 shared	 between	 induced	 and	 repressed	 gene	 lists,	 indicating	
differential	methylation	of	genes	in	specific	pathways	induced	by	VitD	(Figure	4.25	b).	
Most	of	the	significantly	enriched	pathways	originate	from	the	repressed	H3K4me3	gene	
list	 in	 response	 to	 VitD.	 The	 “IFNg	 response”	 pathway	 was	 identified	 as	 statistically	
enriched	in	H3K4me3	VitD	repressed	gene	list	(Figure	4.25	b),	as	with	the	H3K27Ac	VitD	
repressed	 gene	 list.	When	 signal	 at	 regions	 annotated	 to	 genes	was	 visualised	 as	 in	









In	 summary,	pathway	analysis	of	histone	modifications,	 specifically	 containing	
VDR	binding	sites,	 identified	other	members	of	the	IL-6	signalling	cascade,	supporting	

















into	 the	 same	 ontology	 term	 (all	 terms	 are	 statistically	 significantly	 enriched).	 (b)	
Heatmap	 of	 statistically	 significant	 pathways	 from	 H3K4me3	 induced	 and	 H3K4me3	
repressed	gene	lists.	Significant	terms	are	hierarchically	clustered	into	a	tree	based	on	

















VitD	 has	 both	 direct	 and	 indirect	 effects	 on	 CD4+	 T	 cells	 (see	 intro	 5.5.1	
immunoregulatory	actions)	with	 the	majority	of	 studies	 reporting	 that	VitD	 is	able	 to	
directly	 influence	 cytokine	 production	 (Cantorna	 et	 al.,	 2015).	 Despite	 the	 well	
characterised	effects	of	VitD	as	an	inducer	of	the	anti-inflammatory	cytokine	IL-10	and	
inhibitor	 of	 pro-inflammatory	 cytokines,	 especially	 IL-17	 and	 IFNg,	 the	 mechanisms	









found	 nuclear	 localisation	 of	 VDR	 only	 after	 2	 days’	 polyclonal	 activation.	 However,	
Essen	et	al.	study	dynamics	of	VDR	expression	and	localisation	were	not	assessed	after	
addition	 of	 VitD	 and	 key	 experiments	 were	 carried	 out	 in	 bulk	 T	 cells	 without	
discrimination	of	CD4+	and	CD8+.	We	have	performed	a	more	 comprehensive	 spatio-
temporal	analysis	of	VDR	expression	in	CD4+	T	cells,	confirming	increased	expression	and	
nuclear	 translocation	 of	 VDR	 following	 TCR	 activation	 in	 the	 presence	 of	 1,25	 VitD.	
Supporting	our	findings	Kongsbak	et	al.	have	reported	the	redistribution	of	VDR	to	the	
nucleus	 in	 CD4+	T	 cells	 after	 treatment	with	 both	 25	 and	 1,25	 VitD	 by	Western	 blot	
(Kongsbak et al., 2014).		










conditions	 to	ours	 and	 to	 contribute	 to	T	 cell	 regulation	 in	 cultures	with	monocytes,	













VitD	 can	 support	 two	 phenotypically	 distinct	 subpopulations	 of	 CD4+	T	 cell;	 at	 lower	
concentrations	 CD4+FoxP3-IL10+	 and	 at	 higher	 concentrations	 CD4+FoxP3+IL10-	 cells,	
both	populations	being	suppressive	(although	their	suppressive	mechanisms	were	IL-10-
dependent	 and	 IL-10-independent,	 respectively).	 This	 data,	 with	 our	 data,	 suggest	 a	
model	where	as	an	immune	response	develops,	1,25	VitD	concentrations	increase	and	
signals	in	CD4+	T	cells,	and	innate	and	adaptive	immune	responses	could	be	attenuated	








et	 al.,	 2014).	 This	 led	 to	 some	 speculation	 of	 contamination	 by	 monocytes	 in	 our	
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cultures.	However,	 a	 sorting	purity	 of	 over	 99%	along	with	 the	observation	 that	 IL-6	
production	was	not	induced	in	the	sorted	CD4+	naïve	T	cell	compartment	removed	this	





for	 its	 importance	 in	 lineage	commitment	of	Th17	cells.	 Indeed,	 IL-6	 signalling	 in	 the	
presence	of	TGF-b	promotes	differentiation	of	Th17	cells,	with	expression	of	their	key	
transcription	 factor,	 RORgt,	 and	 expression	 of	 the	 pro-inflammatory	 cytokine	 IL-17	




but	 rather	 the	 inflammatory	 context	 in	 which	 IL-6	 signalling	 is	 induced	 is	 important	




cells.	 The	 first	 of	 these	 showed,	 in	 the	 context	 of	 experimental	 autoimmune	







































insight	 into	 which	 sub-populations	 are	 responsible	 for	 producing	 IL-6,	 and	 which	
population	respond	to	 this	 IL-6	 through	 IL-10	production.	 IL-6	 is	classically	a	cytokine	
secreted	by	the	innate	immune	system	and	thus	most	protocols	for	intracellular	staining	







populations	 are	 involved.	 Both	of	 these	questions	 are	 key	 to	 further	 understand	 the	
context	in	which	the	mechanism	might	be	important.	
The	organ	in	the	body	subjected	to	the	highest	levels	of	both	25	and	1,25	VitD	is	




Importantly	 several	 lines	of	evidence	suggest	 that	 IL-6	and	 IL-10	are	beneficial	 in	 the	
context	of	skin	immunity.	Overexpression	of	IL-6	specifically	in	the	skin	of	mice	did	not	
lead	 to	 enhanced	 epidermal	 proliferation	 as	 expected,	 but	 resulted	 in	 a	 thicker	
protective	skin	layer,	with	an	otherwise	normal	program	of	differentiation.	This	led	the	










of	 VitD	 and	 UVB	 therapy	 in	 treatment	 of	 psoriasis.	 In	 accordance	 with	 these	
observations,	 despite	 the	 success	 of	 the	 IL-6R	 blocking	 antibody	 Toc	 to	 treat	




10,	 both	 of	 which	 have	 beneficial	 effects	 in	 the	 context	 of	 skin	 immunity,	 and	 the	
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and	 topical	 VitD	 treatment	 can	 bypass	 this	 deficiency.	 In	 addition,	 individuals	 with	




production,	 which	 along	 with	 inhibition	 of	 IFNg	 and	 IL-17	 lead	 to	 a	 strong	 anti-
inflammatory	CD4+	T	cell	signal.	Thus,	when	this	signalling	process	is	interfered	with	by	
treatment	with	Toc,	the	skin	is	one	of	the	major	organs	effected.	Importantly,	the	VDR	
is	only	 induced	after	activation	of	T	 cells	 and	 thus	may	give	 recruited	T	 cells	 time	 to	
respond	to	stimuli	(infection	or	damage)	before	being	switched	to	a	pro-wound	healing	






later	stages	 in	their	 life	cycle	to	avoid	out	of	control	 immune	responses.	 Indeed	mice	
lacking	 IL-10	 clear	 infection	 with	 Toxoplasma	 gondi	 (Nishikawa	 et	 al.,	 2001)	 and	
Trypanosoma	 cruzi	 (Hunter	 et	 al.,	 1997)	 more	 rapidly	 but	 later	 die	 of	 severe	 tissue	
damage	due	to	uncontrolled	Th1	responses.	As	a	result,	the	idea	of	T	cell	intrinsic	IL-10	
production	 as	 an	 auto-regulatory	 loop	 has	 recently	 gained	momentum	 (Cope	 et	 al.,	
2011),	and	we	suggest	VitD	may	be	instrumental	in	this	pathway	in	certain	contexts.			
In	 this	 chapter,	 we	 next	 showed	 that	 induction	 of	 IL-10	 by	 IL-6	 is	 STAT3	








dependent	on	 total	STAT3	expression	which	 is	 induced	by	VitD.	This	may	explain	 the	
sustained	nature	of	the	observed	pSTAT3	signal.	In	line	with	discussion	of	the	described	







modification	alterations	at	multiple	 loci,	on	a	 large	scale,	following	VitD	treatment,	 in	








binding	 both	 yielded	 networks	 with	 not	 many	 separated	 nodes.	 This	 suggests	 that	
histone	modifications	targeted	by	liganded	VDR	are	mechanistically	linked	in	CD4+	T	cells.		
We	show	clear	evidence	in	this	chapter	that	the	VitD	induced	signaling	pathway	
identified,	 is	 largely	 regulated	 by	 direct	 liganded	 VDR	 binding,	 leading	 to	 histone	
modifications.	VDR	ChIP-seq	unfortunately	did	not	work,	and	quality	control	suggested	
that	this	was	at	the	stage	of	immunoprecipitation	with	VDR	antibody.	As	the	antibody	
clone	 (C-20)	 used	 for	 previous	 VDR	 ChIP-seq	 experiments	 (Handel	 et	 al.,	 2013;	
Ramagopalan	 et	 al.,	 2010)	 had	 been	 discontinued,	 we	 used	 the	 manufacturers	
recommended	replacement	(D-6)	which	was	available	in	highly	concentrated	form	for	
ChIP	experiments.	We	will	attempt	to	repeat	the	VDR	ChIP-seq	experiments	in	the	future	
(see	 section	 4.5.2).	 Using	 a	 parallel	 approach,	 we	 were	 able	 to	 use	 both	 motif	
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identification	 and	 published	 VDR	 ChIP-seq	 data	 to	 provide	 strong	 validation	 of	 VDR	
binding.	We	identified	putative	enhancers,	marked	by	strong	H3K27	acetylation,	of	both	
IL6	and	STAT3	at	which	loci	VDR	binding	and	predicted	VDR	binding	motifs	were	clearly	





such	as	p300	(Haussler et al., 2011; 2013),	we	also	observed	HAT	P300	recruitment	
form	published	ChIP-seq	data	close	to	the	loci	of	increased	acetylation.	Interestingly	one	
of	the	pathways	shown	to	be	targeted	by	VDR	binding	in	both	H3K27Ac	and	H3K4me3	
unchanged	 regions	 was	 covalent	 chromatin	 modifications,	 and	 one	 of	 the	 genes	
annotated	to	this	pathway	was	EP300,	the	gene	encoding	p300.	This	suggest	that	VDR	





both	untreated	 and	VitD	 treated	 cells.	 VDR	binding	 at	 this	 promoter	 region	may	not	
require	 VitD	 but	 increased	 methylation	 here	 requires	 VitD.	 This	 could	 be	 due	 to	
differential	 recruitment	of	histone	modifying	enzymes	 in	 the	presence	of	VitD	 ligand	
compared	to	un-liganded	VDR.	H3K27Ac	was	also	increased	at	this	same	location	but	as	
H3K4me3	is	a	mark	of	enhancer	activity,	this	is	probably	not	an	enhancer	site.	Therefore,	
opening	 of	 the	 locus	 by	 increased	 H3K4	 tri-methylation	 and	 H3K27Ac	 would	 enable	
pSTAT3	binding	at	this	region	which	would	be	epigenetically	inaccessible		in	the	absence	
of	 VitD.	 We	 suggest	 in	 this	 chapter	 that	 VDR,	 unlike	 a	 classical	 TF,	 achieves	 its	
immuneregulatory	function	through	epigenetic	modifications,	opening	up	specific	 loci	
for	other	TFs	to	drive	transcription.		
A	 summary	diagram	of	our	proposed	mechanism	of	 IL-10	production	 through	
histone	modifications	is	presented	in	Figure	4.26.	 It	 is	 important	to	note	that	this	is	a	












which	 then	becomes	 available	 to	 bind	 to	 the	VDR	which	 translocates	 to	 the	 nucleus	
(Figure	4.26	a).	Here	it	binds	to	VDR(DR3)	motifs	at	IL6	and	STAT3	enhancer	sites,	leading	
to	 recruitment	 of	 HAT	 enzymes,	 as	well	 as	 both	 HAT	 and	 histone	methyltransferase	
(HMT)	 enzymes	 at	 the	 promoter	 region	 of	 IL10	 (Figure	 4.26	 c).	 This	 leads	 to	 H3K27	
acetylation	and	H3K4	tri-methylation,	and	ultimately	accessible	chromatin	state	(Figure	
4.26	 c).	 Recruitment	 of	 co-activator	 complex	 and	 core	 transcriptional	 machinery	
(including	RNA	polymerase	 II	 (RNA	pol	 II))	would	 then	 lead	 to	expression	of	 IL-6	 and	
STAT3	(Figure	4.26	d).	IL-6	binding	to	IL-6R	then	leads	to	phosphorylation	of	STAT3	and	
subsequent	pSTAT3	binding	at	promoter	region	of	IL10.	This	leads	to	recruitment	of	co-
activator	complex	and	core	 transcriptional	machinery	at	active	 IL10	promoter	 region,	
marked	by	 increased	H3K37Ac	and	H3K4me3.	This	 finally	 leads	to	expression	of	 IL-10	
protein	(Figure	4.26	c).		
It	 seems	 that	 there	 are	 three	 possible	mechanism	 by	 which	 VDR	 can	 induce	




increase	H3K4me3	at	 the	 tss	not	 induced	by	VDR,	 as	 is	 the	 case	 for	 IL-6.	 Finally,	 un-






as	 a	 mark	 of	 active	 promoters)	 is	 widely	 used,	 it	 is	 not	 without	 its	 limitations.	 For	
example,	 41%	 of	 mesodermal	 enhancers	 in	 D.	 melanogaster	 embryos	 were	 not	
predicted	by	H3K27	acetylation	(Bonn	et	al.,	2012).	In	addition,	there	is	no	evidence	of	a	
mechanistic	 link	 between	 chromatin	 modifications	 and	 active	 enhancers,	 with	 little	
evidence	 for	H3K27Ac	 being	 sufficient	 or	 necessary	 for	 transcription	 (Pengelly	 et	 al.,	
2013).	 As	 such	 this	 is	 one	 of	 the	 major	 limitations	 to	 this	 body	 of	 work.	 Further	
verification	of	enhancer	activity	could	be	carried	out	at	these	putative	enhancer	sites	
using	plasmid	based	systems.	In	these	systems	putative	enhancer	regions	are	typically	




In	 summary,	 this	 chapter	 has	 presented	 mechanistic	 evidence	 of	 a	 VitD	
dependent	 signalling	 loop	 leading	 to	 production	of	 IL-10	 (through	 an	 IL-6	 and	 STAT3	







































the	 involvement	 of	 VitD	 in	 diseases,	 studies	 showing	 direct	 evidence	 of	 VitD	
mechanistically	linked	to	immune	cell	function	will	help	clarify	this	involvement.		
The	suggestion	stemming	from	this	data	of	involvement	of	this	signalling	loop	in	
cutaneous	 immunology	 are	 potentially	 far	 reaching.	 The	 mechanism	 underlying	 the	
potency	of	UVB	therapy	in	psoriasis	is	still	not	known,	and	though	it	likely	involves	non	












The	 first	 question	 is	 whether	 the	 histone	 modifications	 observed	 lead	 to	 actual	
transcriptional	 alterations.	We	 have	 assessed	 the	 final	 protein	 expression	 of	 the	 key	
molecules	 in	 our	 signalling	 pathway,	 this	 will	 need	 to	 be	 clarified	 on	 a	 global	 scale.	
Otherwise	 other	 pathway	 level	 changes	 identified	 by	 histone	 ChIP-seq	 remain	
speculative.	We	have	already	begun	RNA-seq	experiments	to	assess	the	transcriptional	
changes	 due	 to	 VitD	 treatment	 and	 to	 see	 whether	 these	 align	 with	 histone	





































































In	 conclusion,	 we	 have	 shown	 VitD	 can	 fundamentally	 influence	 immune	
responses	at	multiple	levels.	Though	the	work	presented	here	remains	to	be	clarified	in	







































































































































































































































































































































































































































































































































































































































































































































































Both	 membrane	 A	 and	 membrane	 B	 of	 phospho	 array,	 in	 Carrier	 and	 VitD	 treated	








Tables	 indicating	 membrane	 co-ordinates	 for	 all	 proteins	 in	 Appendix	 1	 with	
phosphorylation	site	present	in	membrane	also	indicated.	
	
